Literature DB >> 1569350

Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease.

M White1, C Cirrincione, A Blevins, D Armstrong.   

Abstract

A retrospective analysis of 41 patients with cryptococcal meningitis and AIDS or neoplastic disease was done. Patients with AIDS were younger and predominantly male; they had a shorter duration of prior illness, higher initial serum cryptococcal antigen titers, and lower initial cerebrospinal fluid white blood cell counts than those with neoplastic disease. The median overall survival for patients with AIDS was 9 months compared with 2 months for those with neoplastic disease (P = .004). Seventy-eight percent of patients with AIDS and 43% of those with neoplastic disease were cured or improved 6 months after diagnosis (P = .039). Toxicity from amphotericin B and flucytosine was similar for both groups. One patient with AIDS relapsed. Multivariate predictors of survival included headache (P = .007) and an AIDS diagnosis (P = .009). Examination of outcomes for other opportunistic infections associated with AIDS and other immunosuppressive illness may distinguish prognostic features for different patient populations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1569350     DOI: 10.1093/infdis/165.5.960

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target.

Authors:  M Del Poeta; D L Toffaletti; T H Rude; C C Dykstra; J Heitman; J R Perfect
Journal:  Genetics       Date:  1999-05       Impact factor: 4.562

2.  Cryptococcal Meningitis: A Clinicopathological Account of Seven Cases Encountered in a Military Setting.

Authors:  K Kapila; Y V Sharma; J Kotwal; A Banerjee; J Kaur
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 3.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

4.  Quantitation of cellular components in Cryptococcus neoformans for system biology analysis.

Authors:  Arpita Singh; Asfia Qureshi; Maurizio Del Poeta
Journal:  Methods Mol Biol       Date:  2011

Review 5.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Authors:  T G Mitchell; J R Perfect
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

6.  Prediction of unfavorable outcomes in cryptococcal meningitis: results of the multicenter Infectious Diseases International Research Initiative (ID-IRI) cryptococcal meningitis study.

Authors:  I N Hakyemez; H Erdem; G Beraud; M Lurdes; A Silva-Pinto; C Alexandru; B Bishop; F Mangani; X Argemi; M Poinot; R Hasbun; M Sunbul; M Akcaer; S Alp; T Demirdal; K Angamuthu; F Amer; E Ragab; G A Shehata; D Ozturk-Engin; N Ozgunes; L Larsen; S Zimmerli; O R Sipahi; E Tukenmez Tigen; G Celebi; N Oztoprak; A C Yardimci; Y Cag
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-12-08       Impact factor: 3.267

Review 7.  Cryptococcosis in solid organ transplant recipients: current state of the science.

Authors:  Nina Singh; Francoise Dromer; John R Perfect; Olivier Lortholary
Journal:  Clin Infect Dis       Date:  2008-11-15       Impact factor: 9.079

8.  A fatal case of AIDS-defining meningoencephalitis by C. neoformans, sensitive to antifungal therapy.

Authors:  S Mohammad-Khani; B Otremba; R Klein; H H Capelle; F Logemann; F C Bange; R E Schmidt; M Stoll
Journal:  Eur J Med Res       Date:  2010-11-25       Impact factor: 2.175

9.  Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study.

Authors:  Françoise Dromer; Simone Mathoulin-Pélissier; Odile Launay; Olivier Lortholary
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

10.  Major role for amphotericin B-flucytosine combination in severe cryptococcosis.

Authors:  Françoise Dromer; Claire Bernede-Bauduin; Didier Guillemot; Olivier Lortholary
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.